Regenxbio Inc (RGNX NASDAQ) stock market data APIs
$6.8092
-0.93(-13.7%)
as of May 21, 2026
Try our APIs with
free plan!
Regenxbio Inc Financial Data Overview
Price chart is built with
Anychart
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Prev. Close
6.8092
Open
5.8828
High
6.8325
Low
5.8048
52 wk Range
5.455-16.19
Market Cap
307 M
Shares Outstanding
51 698 K
Revenue
87 822 K
EPS
-1.72
Beta
1.121
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Regenxbio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Regenxbio Inc data using free add-ons & libraries
Get Regenxbio Inc Fundamental Data
Regenxbio Inc Fundamental data includes:
- Net Revenue: 87 822 K
- EBITDA: -241 170 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-06
- EPS/Forecast: -0.5017
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Regenxbio Inc News
New
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway
Regenxbio Inc (NASDAQ:RGNX) is one of the best gene therapy stocks to buy in 2026. On May 14, Regenxbio reported its Q1 2026 financial results and provided operational updates. The company exited the ...
Regenxbio outlines potential accelerated approval path for RGX-202 in 2027 following pivotal Phase III primary endpoint result
Earnings Call Insights: REGENXBIO (RGNX) Q1 2026 MANAGEMENT VIEW * "Earlier this morning, we announced positive top line data from the pivotal trial of RGX-202, our potential best-in-class investi...
Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint
(Updates with latest stock price movement in the headline and first paragraph, Q1 earnings in the se PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Regenxbio Shares Rise After Positive Duchenne Trial Results
medical research 10 ©Pixnio Regenxbio (NASDAQ:RGNX) shares gained more than 4% in premarket trading Thursday after investors focused on encouraging clinical trial results for the company’s Duchenn...
Get Regenxbio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
